NCT06729840 Intralesional Treatment of Keloids
| NCT ID | NCT06729840 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Sohag University |
| Condition | Scar, Hypertrophic |
| Study Type | INTERVENTIONAL |
| Enrollment | 45 participants |
| Start Date | 2024-12-01 |
| Primary Completion | 2025-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 45 participants in total. It began in 2024-12-01 with a primary completion date of 2025-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Intralesional injection in treatment of keloid
Eligibility Criteria
Inclusion Criteria: Both sex aged 18-60 having keloid \- Exclusion Criteria: * pregnancy , lactation Skin disease
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06729840 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Scar, Hypertrophic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06729840 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 45 participants.
Is NCT06729840 currently recruiting?
Yes, NCT06729840 is actively recruiting participants. Contact the research team at samaalaa.867@gmail.com for enrollment information.
Where is the NCT06729840 trial being conducted?
This trial is being conducted at Sohag, Egypt.
Who is sponsoring the NCT06729840 clinical trial?
NCT06729840 is sponsored by Sohag University. The trial plans to enroll 45 participants.